Company intelligence / Profile preview
IngenOx Therapeutics
Oxford, Oxfordshire, United Kingdomingenox.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Phase 2
01
Overview
IngenOx is advancing a clinical and pre-clinical pipeline of precision therapies and vaccines for different cancer indications, with a focus on 'cold tumors' that are poorly recognized by the immune system. Their lead drug Zabinostat (also known as Zabadinostat/CXD101) is in Phase 2 trials for multiple cancer indications.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesPrecision therapiesVaccinesSynthetic peptide vaccineTherapeutic vaccine
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
AstraZenecaRocheMerck Sharp & DohmeCancer Research UKNational Institute for Health ResearchNuance Biotech
Beyond the preview
Go deeper on IngenOx Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IngenOx Therapeutics.